BridgeBio Inventory Surges on Dwarfism Drug Information. It is Unhealthy Information for BioMarin.

Textual content measurement

BridgeBio Pharma
inventory was hovering after the biopharmaceutical firm reported optimistic leads to a Section two medical trial for an experimental therapy for achondroplasia, the commonest kind of short-limbed dwarfism.

On Monday, BridgeBio (ticker: BBIO) mentioned in a information launch that its experimental drug Infigratinib confirmed an annualized enchancment of three.03 centimeters in so-called peak velocity, or good points in peak, in a examine together with 10 kids.

Based mostly on these outcomes, BridgeBio says it has began enrolling kids within the run-in for a Section 3 trial.

“These outcomes attain a brand new tier of efficacy, and paired with our differentiated security and comfort profile, present us the chance to serve kids with achondroplasia and different skeletal dysplasias,” Chief Govt Neil Kumar mentioned within the information launch.

Shares of BridgeBio have been on tempo for his or her largest p.c enhance on report, hovering 71% Monday to $18.47, in keeping with Dow Jones Market Information. The inventory has jumped 145% this yr.

BioMarin Pharmaceutical
(BMRN) shares have been down 5.5% following the information to $95.64. If the inventory closes at that degree, it might be the biggest proportion lower since October and lowest shut since November 2022.

In November 2021, BioMarin mentioned that it obtained approval from the Meals and Drug Administration for Voxzogo, a therapy for kids with achondroplasia. The introduction of one other drug on this market would means competitors for BioMarin. The corporate earned $67 million from Voxzogo in its fourth quarter.

Write to Angela Palumbo at angela.palumbo@dowjones.com